WARNING LETTER
VapeCentric, Inc.
MARCS-CMS 607375 —
April 27, 2020
Delivery Method:
VIA UPS and Electronic Mail
Product:
Tobacco
Recipient:
Recipient Name
Michael Daneshrad
VapeCentric, Inc.
30101 Agoura Court, Suite 233
Agoura Hills
,
CA
91301
United States
sales@vapecentric.com
mike@vapecentric.com
Issuing Office:
Center for Tobacco Products
10903 New Hampshire Avenue
Silver Spring
,
MD
20993
United States
WARNING LETTER
Dear Michael Daneshrad:
The Center for Tobacco Products of
the U.S.
Food and Drug Administration (FDA) recently reviewed the website
https://vapecentric.com
and determined that an e-liquid product listed there is offered for sale or distribution to customers in the United States.
Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (
FD&C Act
) (21 U.S.C. § 321(rr)), this product is a tobacco product because it is made or derived from tobacco and intended for human consumption.  Certain tobacco products, including e-liquids, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b))
and 21 C.F.R. § 1100.1
.  Therefore, e-liquids are required to be in compliance with the requirements in the FD&C Act.
Please be aware that, effective
August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the Act.  These products include, but are not limited to, electronic nicotine delivery systems (ENDS) (including e-cigarettes), e-liquids, cigars, and pipe tobacco.
See
Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at
https://federalregister.gov/a/2016-10685
.
The FD&C Act requires “new tobacco products” to have premarket authorization.  A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)).  Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report und
e
r sec
t
ion 905(j
)
(
1
)(A
)(i
i
) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3).
A New Tobacco Product Without Required Marketing Authorization is Adulterated and Misbranded
Our review of the website https://vapecentric.com
revealed that you offer for sale or distribution to customers in the United States the following
e-liquid product without a marketing authorization order: Pink Sticks.
The e-liquid product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007.
This
product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and is not otherwise exempt from the marketing authorization requirement.  Therefore,
this
product is adulterated under section 902(6)(A) of the FD&C Act
.  In addition, it is
misbranded under section 903(a)(6) of the FD&C Act because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&C Act.
Additional Considerations
FDA finds your product particularly concerning because the Pink Sticks e-liquid product (see Exhibit A) appears to imitate food products that are typically marketed toward and/or appealing to children.  Specifically, the packaging for this e-liquid product looks very similar to
Pocky Strawberry biscuit sticks
(see Exhibit B), which is commonly marketed toward and/or appeal to children.  FDA is concerned about the rising youth appeal and dramatic rise in youth use of ENDS products, including e-liquids. Any efforts to entice minors to use tobacco products are of concern to FDA.  Sales of such products to minors are prohibited, and FDA is concerned that your actions likely encourage unlawful sales, maintain or increase youth use, and contribute to the public health and safety concerns associated with ENDS products, including e-liquids.
Conclusion and Requested Actions
It is your responsibility to ensure that your tobacco products and all related labeling and/or advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments
comply with each applicable provision of the FD&C Act and FDA’s implementing regulations.
Failure to address any violations of the type described above may result in FDA’s initiating action, including, but not limited to, civil money penalties, seizure, and/or injunction.  However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act.
Please note that adulterated and misbranded tobacco products offered for import into the United States are subject to detention and refusal of admission.
The violations discussed in this letter do not necessarily constitute an exhaustive list.  You should promptly correct any violations that are referenced above, as well as violations that are the same as or similar to those stated above,
and take any necessary actions to bring your tobacco products into compliance with the FD&C Act.
Please submit a written response to this letter within 15 working days from the date of receipt describing your corrective actions, including the dates on which you discontinued the violative labeling, advertising, sale, and/or distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act.  If you do not believe that your products are in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.  You can find the FD&C Act through links on FDA’s homepage at
http://www.fda.gov
.
Please note your reference number, RW2001268, in your response and direct your response to the following address:
DPAL-WL Response, Office of Compliance and Enforcement
FDA Center for Tobacco Products
c/o Document Control Center
Building 71, Room G335
10903 New Hampshire Avenue
Silver Spring, MD 20993-0002
If you have any questions about the content of this letter, please contact Ele Ibarra-Pratt at (301) 796-9235
or via email at
CTPCompliance@fda.hhs.gov
.
Sincerely,
/S/
Ann Simoneau, J.D.
Director
Office of Compliance and Enforcement
Center for Tobacco Products
VIA UPS and Electronic Mail
cc:
Michael Daneshrad
5015 Blackpool Avenue
Oak Park, CA 91377
GoDaddy.com, LLC
abuse@godaddy.com
Google, LLC
google-cloud-compliance@google.com
Content current as of:
04/27/2020
Regulated Product(s)
Tobacco